title: Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
abstract: Although Chronic Myeloid Leukaemia (CML) can be treated successfully with allogeneic bone marrow transplantation (BMT), leukaemia relapse remains a significant clinical problem. Molecular monitoring of the post transplant marrow can be useful in predicting relapse particularly in CML patients where the Philadelphia chromosome or its molecular counterpart, the BCR-ABL fusion messenger RNA can be used as a leukaemia specific marker of minimal residual disease (MRD). We have investigated chimaerism (using polymerase chain reaction of short tandem repeat sequences (STR-PCR)) and MRD status (using reverse transcriptase PCR of the BCR-ABL fusion mRNA) in a serial fashion in 18 patients who were in clinical and haematological remission post allogeneic BMT for chronic phase CML. Eleven patients exhibited complete donor chimaerism with no evidence of minimal residual disease. Five patients had transient or low level stable MC. Late MC and MRD was observed in two patients who relapsed > 6 years after T cell depleted BMT for CML. Thus STR-PCR is an appropriate screening test in the post transplant setting for CML patients, but those patients exhibiting mixed haemopoietic chimaerism should also be monitored using a leukaemia specific sensitive molecular assay.
authors.affiliation: Department of Haematology/Oncology St James Hospital, Dublin, Ireland.
authors.forename: N
authors.initials: N
authors.lastname: Gardiner
authors.forename: M
authors.initials: M
authors.lastname: Lawler
authors.forename: J
authors.initials: J
authors.lastname: O'Riordan
authors.forename: M
authors.initials: M
authors.lastname: De'Arce
authors.forename: S R
authors.initials: SR
authors.lastname: McCann
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D016572:Cyclosporine / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000032:analysis / Q000096:biosynthesis; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008212:Lymphocyte Depletion; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014158:Transcription, Genetic; D018183:Transplantation Chimera
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016044:Fusion Proteins, bcr-abl; D008727:Methotrexate